Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
elotuzumab + selinexor + dexamethasone
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
Elotuzumab + selinexor + dexamethasone is a combination regimen under investigation for the treatment of relapsed or refractory multiple myeloma. Elotuzumab is a monoclonal antibody that targets SLAMF7 (also known as CS1) on myeloma and natural killer (NK) cells, activating NK cells and tagging myeloma cells for immune-mediated destruction. Selinexor is an orally bioavailable small molecule that selectively inhibits exportin 1 (XPO1), blocking nuclear export of tumor suppressor proteins and other regulatory proteins, leading to cancer cell death. Dexamethasone is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive properties, commonly used in multiple myeloma regimens to enhance antitumor effects[3][6][7]. This combination leverages complementary mechanisms—immune activation, inhibition of oncogenic protein transport, and anti-inflammatory action—to target resistant or relapsed disease.
- Other names
- none
02
Targets
GR (Glucocorticoid receptor)XPO1 (Exportin-1)SLAMF7 (Signaling lymphocytic activation molecule family member 7)
Beyond the preview
Go deeper on elotuzumab + selinexor + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on elotuzumab + selinexor + dexamethasone.